LOVE and 8CB0 Related Headlines
Go Back- Cannara Establishes Automatic Share Purchase Plan
- Cannara Announces Normal Course Issuer Bid
- Cannara Reports Record Q3 Revenues and Continued Profitability Accompanied By Expanding National Distribution and Accelerated Capacity Expansion
- Cannara signs cannabis supply deal with Curaleaf International
- Cannara Announces a Long-Term International Cannabis Supply Agreement with Curaleaf International Limited
- Cannara to Announce Fiscal Q3 2026 Financial Results on July 15, 2026
- Cannara Secures Exclusive Canadian Rights to Blue River's Ampersand™ Live Rosin Infusion Technology
- Cannara Biotech acquires Medican Organic for $2.8 million
- Cannara Completes Acquisition of Medican Organic Inc.
- Cannara Reports Q2 Fiscal 2026 Results with Continued Profitability, Strong Operating Cash Flow and #1 Retail Market Share in Québec
- Cannara to Announce Fiscal Q2 2026 Financial Results on April 14, 2026
- Cannara Announces Graduation to the Toronto Stock Exchange
- Cannara to Host Investor Webcast on February 19th, 2026
- Cannara Biotech raises C$6.3 million in private placement at premium
- Cannara Announces Strategic C$6.3 Million Non-Brokered Private Placement Priced at C$2.10 per Common Share
- Cannara Announces Conditional Approval to List on the Toronto Stock Exchange
- Cannara Reports Q1 Fiscal 2026 Results, Delivers New Record Financial Results, Extends Market Share Gains and Advances Disciplined Expansion Strategy
- Cannara Achieves OTCQX Qualification and Announces Release of Fiscal Q1 2026 Financial Results on January 26, 2026
- Cannara Achieves #1 Market Share Position in Québec as of December 2025 and Provides Update on Québec Vape Category Launch
- Cannara Biotech Delivers Record Fiscal 2025 Revenue and Profitability, Achieves First Year of Positive Retained Earnings
- Cannara Biotech Inc. to Announce Fiscal Q4 2025 and Fiscal Year 2025 Financial Results on November 24, 2025 and Provides Board Update
LOVE and 8CB0 Related Press Releases
Go Back- Cannara Establishes Automatic Share Purchase Plan
- Cannara Announces Normal Course Issuer Bid
- Cannara Reports Record Q3 Revenues and Continued Profitability Accompanied By Expanding National Distribution and Accelerated Capacity Expansion
- Cannara Announces a Long-Term International Cannabis Supply Agreement with Curaleaf International Limited
- Cannara to Announce Fiscal Q3 2026 Financial Results on July 15, 2026
- Cannara Secures Exclusive Canadian Rights to Blue River's Ampersand™ Live Rosin Infusion Technology
- Cannara Completes Acquisition of Medican Organic Inc.
- Cannara Reports Q2 Fiscal 2026 Results with Continued Profitability, Strong Operating Cash Flow and #1 Retail Market Share in Québec
- Cannara to Announce Fiscal Q2 2026 Financial Results on April 14, 2026
- Cannara Announces Graduation to the Toronto Stock Exchange
- Cannara to Host Investor Webcast on February 19th, 2026
- Cannara Announces Strategic C$6.3 Million Non-Brokered Private Placement Priced at C$2.10 per Common Share
- Cannara Announces Conditional Approval to List on the Toronto Stock Exchange
- Cannara Reports Q1 Fiscal 2026 Results, Delivers New Record Financial Results, Extends Market Share Gains and Advances Disciplined Expansion Strategy
- Cannara Achieves OTCQX Qualification and Announces Release of Fiscal Q1 2026 Financial Results on January 26, 2026
- Cannara Achieves #1 Market Share Position in Québec as of December 2025 and Provides Update on Québec Vape Category Launch
- Cannara Biotech Delivers Record Fiscal 2025 Revenue and Profitability, Achieves First Year of Positive Retained Earnings
- Cannara Biotech Inc. to Announce Fiscal Q4 2025 and Fiscal Year 2025 Financial Results on November 24, 2025 and Provides Board Update
